NRx Pharmaceuticals has initiated commercial manufacturing of its preservative-free ketamine product in anticipation of approval under the Generic Drug User Fee Act in Summer 2026. The company transmitted an initial GMP manufacturing order to its US-based manufacturer after completing confirmatory GMP audits.
Manufacturing Innovation and Advantage
NRx’s product is the first US-manufactured preservative-free ketamine presentation. The company manufactures via a blow-fill-seal process that achieves more than 10-fold higher manufacturing throughput than traditional sterile bottling techniques relying on glass vials and traditional seals. NRx’s ketamine differs from existing products by not containing Benzethonium Chloride, a known toxic preservative that is no longer allowed in new drugs and cannot even be included in hand cleansers and topical antiseptics according to FDA policy.
Supply Shortage Context
The manufacturing order follows stability observed in more than 3 manufactured registration batches and the company’s successful third-party audit of the manufacturing facility. The company expects initial manufacturing to be sufficient to support significant market penetration in first-year sales and can be readily scaled based on the blow-fill-seal process. As of April 7, 2026, sterile intravenous ketamine remains listed on the American Society of Health-System Pharmacists national drug shortage database, with ongoing supply constraints across multiple manufacturers, including product discontinuations, back orders, and reliance on short-dated inventory.
Regulatory and Clinical Status
NRX-100 has been awarded Fast Track Designation for the treatment of suicidal ideation in depression, including bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 for treating suicidal ideation in patients with depression, including bipolar depression. Dr. Jonathan Javitt, Chairman and CEO, said: “NRx thanks its manufacturing partner for the care and support invested in this project and looks forward to serving Americans with a safe and convenient US-made ketamine product. We hope to alleviate the supply shortages that have frequently been reported.”
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.globenewswire.com/news-release/2026/05/05/3287507/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Announces-Initiation-of-Commercial-Manufacturing-for-Preservative-Free-Ketamine.html